Plain-English translation of NCT07619599 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This pilot study is testing a new imaging agent called 64Cu-DOTA- that can help doctors better understand how your lung cancer is responding to treatment. You would receive your standard immunotherapy medication () along with a special type of radiation therapy called SBRT, while researchers use the new imaging scan to track how your tumors are changing.
Some patients taking immunotherapy develop cancer in just a few spots while the rest of their cancer stays controlled. Doctors need better tools to see which tumors are still responding to immunotherapy and which ones need additional targeted radiation. This new imaging agent could help guide treatment decisions more accurately.
You likely qualify if…
You likely don't qualify if…
Over about 6 weeks, you would receive your regular infusions and get two special imaging scans using the new agent (about 2 days apart and again 6 weeks later). Between these scans, you would receive focused radiation therapy over 1–2 weeks targeting specific tumor spots. You would also have standard CT scans as part of the study. After completing the main study activities, you would be followed for 1 year to monitor your health and how well the treatment worked.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States